Bristol Myers Squibb's Claude Deployment: What Actually Shipped

Everyone's talking about AI in enterprise, but Bristol Myers Squibb actually *shipped* something substantial with Claude. Most "AI deployments" are pilot programs or small internal tools. BMY's move isn't just a press release; it's a pipeline-wide integration that's already shifting how analysts view their stock. This is the unglamorous part of AI that actually moves the needle. The actual delta here is scale. They're not just testing; they're operationalizing Claude for drug discovery, clinical trials, and regulatory processes. This systematic approach is what separates a proof-of-concept from a strategic asset. It's about systemic efficiency, not just a flashy demo. For builders, this means the focus needs to be on robust integration and measurable impact. Forget the hype cycles. If you can't show how your AI system changes workflows or improves a core business metric, it's just a toy. BMY shows how to build for actual adoption. I break down one real-world AI deployment every morning. One email, free, no fluff. Link in bio.